The Street's story in 2021 was tidy: mRNA equals vaccine, vaccine equals pandemic, pandemic ends, revenue falls off a cliff. It is a clean narrative. It is also incomplete, and the patent filings are where you see why.
Here is the single fact that complicates the consensus: by 2021, mRNA filings were already pointed well beyond infectious disease. Publication US20210386843A1, titled simply mRNA Vaccine, includes claims tied to cancer-relevant antibody targets — the same delivery idea aimed at oncology rather than a virus.
Acknowledge the bull case first, because it deserves it: the platform really is flexible. The delivery work, like the lipid-peptide nanocomplex in US20210170046A1 for getting mRNA into cells, is genuinely reusable across diseases. If you can deliver the message reliably, you can in principle deliver many messages.
But read the risk factors. A patent filing is an option, not a product. The gap between 'we have claims on mRNA-encoded cancer therapy' and 'we have an approved, reimbursed cancer drug' is enormous, expensive, and littered with failed trials. Breadth of filing tells you ambition, not outcome.
So the contrarian read cuts both ways. The bears who priced mRNA as a single expiring product were missing the platform optionality the patents make obvious. But the bulls who treated every filing as future revenue were buying lottery tickets and calling them earnings.
The honest position is the boring one: the 2021 patent record proves the platform was always broader than the vaccine. Whether that breadth becomes money is a separate question the filings cannot answer — and that is precisely the gap the market kept mispricing in both directions.